19 jul: UPDATE: Danaher 2nd Quarter Net Down 7.5%; Profit View Cut
19 jul: Avio Profit Up Partly On Strength of Civilian Business
19-07-2012 15:18:00

Array BioPharma Reaches $8.5 Million Milestone in Amgen Diabetes Agreement

Relateret indhold
Relateret debat
24 jul - 
Er også med i Dara. Den skal nok stige til i hvert fald..
24 jul - 
Tak og liover da:)
24 jul - 
Er med på Dara kende ikke lige den anden pøj pøj

By Saabira Chaudhuri

Array BioPharma Inc. (ARRY) has reached a $8.5 million milestone in its agreement with Amgen Inc. (AMGN) to develop a drug to treat diabetes.

Array--a biopharmaceutical company focused on developing small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases--entered the agreement, which is for worldwide development of small-molecule glucokinase activators, including a drug called AMG 151, with Amgen in December 2009.

Under the terms, Amgen paid an up front fee of $60 million. Array is entitled to receive up to about $658 million in additional aggregate milestone payments if all clinical and commercialization milestones specified in the agreement for AMG 151 and at least one backup compound are achieved. Array will also receive royalties on sales of any approved drugs developed under the agreement.

Glucokinase is the enzyme that acts as a glucose sensor in the pancreas and liver. The activation of glucokinase lowers glucose levels by enhancing the ability of the pancreas to sense glucose, which leads to increased insulin production. It also increases the update of blood glucose by the liver.

On Thursday, Array said AMG 151 has previously been found effective in controlling blood glucose. It said the milestone was achieved after Amgen reached a pre-defined patient enrollment level in a Phase 2 clinical trial.

In April, Array said its loss for the fiscal third quarter had narrowed on higher revenue coupled with lower operating expenses.

Shares were up 2.76% in recent premarket trading to $4.10. The stock is up 61% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 19, 2012 09:18 ET (13:18 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Danske: Bestyrelsesmedlem køber aktier for 236.748 kr.

24-07-2014 16:39:27
Carol Sergeant, der er medlem af bestyrelsen hos Danske Bank, har købt aktier i banken for samlet 236.748 kr. torsdag.Det fremgår af en insidermeddelelse torsda..

Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget

24-07-2014 12:46:29
Amerikanske Eli Lilly, der er en stor konkurrent til Novo Nordisk på insulinmarkedet, leverede tocifret vækst i salget af sit bedst sælgende insulin, Humalog, i..

Aktier/åbning: Danske Bank dominerer efter dukseregnskab

24-07-2014 09:29:28
Danske Bank er der store historie torsdag morgen på det danske aktiemarked, efter at banken har leveret sit bedste kvartalsresultat siden 2007. Det bliver beløn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Q2: Massiv fremgang og opjustering
2
Aktier/tendens: Danske Bank stjæler rampelyset
3
Aktier/åbning: Danske Bank dominerer efter dukseregnskab
4
Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget
5
TDC/analytikere: Telia-køb af Telenor Danmark mest sandsynligt

Relaterede aktiekurser

Array BioPharma Inc 4,28 -1,6% Fald i aktiekurs
Amgen Inc 122,26 0,2% Stigning i aktiekurs
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juli 2014 05:39:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB6 - 2014-07-25 05:39:43 - 2014-07-25 05:39:43 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x